tbuckley/cabot-search huggingface dataset:
Structure–activity relationship of pyrazol-4-yl-pyridine derivatives and identification of a radiofluorinated probe for imaging the muscarinic acetylcholine receptor M4
Authors: Ahmed Haider, Xiaoyun Deng, Olivia Mastromihalis, Stefanie K. Pfister, Troels E. Jeppesen, Zhiwei Xiao, Vi Pham, Shaofa Sun, Jian Rong, Chunyu Zhao, Jiahui Chen, Yinlong Li, Theresa R. Connors, April T. Davenport, James B. Daunais, Vahid Hosseini, Wenqing Ran, Arthur Christopoulos, Lu Wang, Celine Valant, Steven H. Liang
Journal: Acta Pharmaceutica Sinica B (2022)

There is an accumulating body of evidence implicating the muscarinic acetylcholine receptor 4 (M4) in schizophrenia and dementia with Lewy bodies, however, a clinically validated M4 positron emission tomography (PET) radioligand is currently lacking. As such, the aim of this study was to develop a suitable M4 PET ligand that allows the non-invasive visualization of M4 in the brain. Structure-activity relationship studies of pyrazol-4-yl-pyridine derivates led to the discovery of target compound 12- a subtype-selective positive allosteric modulator (PAM). The radiofluorinated analogue, [18F]12, was synthesized in 28 ± 10% radiochemical yield, >37 GBq/μmol and an excellent radiochemical purity >99%. Initial in vitro autoradiograms on rodent brain sections were performed in the absence of carbachol and showed moderate specificity as well as a low selectivity of [18F]12 for the M4-rich striatum. However, in the presence of carbachol, a significant increase in tracer binding was observed in the rat striatum, which was reduced by >60% under blocking conditions, thus indicating that orthosteric ligand interaction is required for efficient binding of [18F]12 to the allosteric site. Remarkably, however, the presence of carbachol was not required for high specific binding in the non-human primate (NHP) and human striatum, and did not further improve the specificity and selectivity of [18F]12 in higher species. These results pointed towards significant species-differences and paved the way for a preliminary PET study in NHP, where peak brain uptake of [18F]12 was found in the putamen and temporal cortex. In conclusion, we report on the identification and preclinical development of the first radiofluorinated M4 PET radioligand with promising attributes. The availability of a clinically validated M4 PET radioligand harbors potential to facilitate drug development and provide a useful diagnostic tool for non-invasive imaging.
MO19-3 PD-L1 expression in patients with HER2-negative advanced breast cancer: A multicenter retrospective study
Authors: Junichiro Watanabe, Sugino Takashi, Muramatsu Koji, Morita Satoshi, Hidaka Yu, Nakamoto Shogo, Ito Mitsuya, Ohtani Shoichiro, Ikeda Masahiko
Journal: Annals of Oncology (2022)
MO39-4 An association between p16/MTAP status and the efficacy of cisplatin-plus-pemetrexed or nivolumab treatment of MPM
Authors: Yuki Shinno, Yukiko Shimoda, Ken Masuda, Yuji Matsumoto, Yusuke Okuma, Tatsuya Yoshida, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Noriko Motoi, Yasushi Yatabe, Yuichiro Ohe
Journal: Annals of Oncology (2022)
MO37-1 Treatment outcome and relapse of serious immune-related adverse events in patients with solid malignancies
Authors: Seira Owaki, Kazuhiro Shiraishi, Mariko Sato, Riko Nishibori, Kyoko Kato, Keiji Sugiyama, Yoriko Funahashi, Miki Yoshida, Hirotaka Inoue, Yoshihito Kogure, Nobuyoshi Minemura, Chiyoe Kitagawa
Journal: Annals of Oncology (2022)
O2-5 Impact of proton pump inhibitors and antibiotics on efficacy of nivolumab in patients with R/M HNSCC
Authors: Akihisa Wada, Tomohiro Enokida, Susumu Okano, Masanobu Sato, Hideki Tanaka, Yuri Ueda, Takao Fujisawa, Naohiro Takeshita, Nobukazu Tanaka, Makoto Tahara
Journal: Annals of Oncology (2022)
O6-3 The significance of ultra-low EGFR T790M mutations on EGFR-TKI efficacy in patients with NSCLC -the WJOG13119L study
Authors: Takeshi Masuda, Satoru Miura, Hidenori Koso, Kazuhiro Yanagihara, Tatsuro Okamoto, Hiroyasu Shoda, Junichi Shimizu, Nobuhiro Kanaji, Satoshi Hara, Shinya Sakata, Takaaki Tokito, Kosuke Kashiwabara, Kazuo Nishikawa, Hiroshi Watanabe, Ken Maeno, Shigeki Suzuki, Daisuke Hayakawa, Nobuyuki Yamamoto, Kazuhiko Nakagawa, Hattori Noboru
Journal: Annals of Oncology (2022)
O1-1 Second-line tislelizumab vs chemotherapy in advanced or metastatic ESCC: RATIONALE 302 Japanese subgroup
Authors: Hiroki Hara, Taroh Satoh, Takashi Kojima, Satoru Motoyama, Takahiro Tsushima, Yu Sunakawa, Morihito Okada, Aiyang Tao, Ningning Ding, Ken Kato
Journal: Annals of Oncology (2022)
PS4-3 A phase III trial of pimitespib (TAS-116) in patients with advanced gastrointestinal stromal tumor: CHAPTER-GIST-301
Authors: Akira Sawaki, Yukinori Kurokawa, Yoshitaka Honma, Yoichi Naito, Shiro Iwagami, Hideo Baba, Yoshito Komatsu, Toshirou Nishida, Toshihiko Doi
Journal: Annals of Oncology (2022)
P75-4 Nanoliposomal irinotecan plus 5-fluorouracil, leucovorin as post-gemcitabine-based therapy in pancreatic cancer
Authors: Chinatsu Mori, Masato Ozaka, Takafumi Mie, Takaaki Furukawa, Yuto Yamada, Takeshi Okamoto, Tsuyoshi Takeda, Akiyoshi Kasuga, Masato Matsuyama, Takashi Sasaki, Naoki Sasahira
Journal: Annals of Oncology (2022)
MO9-2 Usefulness of EUS-FNA for diagnosis of intraperitoneal tumors other than hepatobiliary and pancreatic cancer
Authors: Toshiharu Hirose, Yuta Maruki, Susumu Hijioka, Go Ikeda, Mao Okada, Yumi Murashima, Natsumi Yamada, Kotaro Takeshita, Kosuke Maehara, Yuki Kawasaki, Tomoyuki Satake, Akihiro Oba, Yoshikuni Nagashio, Shunsuke Kondo, Chigusa Morizane, Hideki Ueno, Takuji Okusaka
Journal: Annals of Oncology (2022)
Improving cancer immunotherapy via co-delivering checkpoint blockade and thrombospondin-1 downregulator
Authors: Qingqing Xiao, Xiaotong Li, Chang Liu, Yuxin Jiang, Yonglong He, Wanting Zhang, Helena S. Azevedo, Wei Wu, Yuanzheng Xia, Wei He
Journal: Acta Pharmaceutica Sinica B (2022)

The use of checkpoint-blockade antibodies is still restricted in several malignancies due to the modest efficacy, despite considerable success in anti-tumor immunotherapy. The poor response of cancer cells to immune destruction is an essential contributor to the failure of checkpoint therapy. We hypothesized that combining checkpoint therapy with natural-product chemosensitizer could enhance immune response. Herein, a targeted diterpenoid derivative was integrated with the checkpoint blockade (anti-CTLA-4) to improve immunotherapy using thermosensitive liposomes as carriers. In vivo, the liposomes enabled the co-delivery of the two drug payloads into the tumor. Consequently, the regulatory T cell proliferation was restrained, the cytotoxic T cell infiltration was enhanced, and the profound immunotherapeutic effect was achieved. In addition, the immunotherapeutic effect of another clinically used checkpoint antibody, anti-PD-1, also benefited from the diterpenoid derivative. Of note, our mechanism study revealed that the targeted diterpenoid derivative increased the sensitivity of cancer cells to immune attack via THBS1 downregulation and the resultant destruction of THBS1-CD47 interaction. Collectively, co-delivering THBS1 inhibitor and checkpoint blockade is promising to boost cancer immunotherapy. We first time discovered that THBS1 suppression could strengthen checkpoint therapy.
MO20-6 CADM1 and SPC25 gene mutations in lung cancer patients with idiopathic pulmonary fibrosis
Authors: Aya Fukuizumi, Rintaro Noro, Masahiro Seike, Akihiko Miyanaga, Yuji Minegishi, Miwako Omori, Mamiko Hirao, Kuniko Matsuda, Shinobu Kunugi, Kazutaka Nishiwaki, Masahiro Morimoto, Haruka Motohashi, Hayato Ohwada, Jitsuo Usuda, Akihiko Gemma
Journal: Annals of Oncology (2022)
P38-3 Clinical outcomes of next-generation sequencing test for breast cancer at the National Cancer Center Hospital
Authors: Rumi Nishimura, Sudo Kazuki, Motoko Arakaki, Ayumi Saitou, Yohei Chiba, Momoko Tokura, Chiharu Mizoguchi, Shousuke Kita, Kasumi Yamamoto, Shu Yazaki, Hitomi Okuma, Yuki Kojima, Tadaaki Nishikawa, Emi Noguchi, Tatsunori Shimoi, Kan Yonemori
Journal: Annals of Oncology (2022)
O8-4 KEYNOTE-042: 5-year update of first-line pembrolizumab in Asian patients with locally advanced/metastatic PD-L1-positive NSCLC
Authors: Kaoru Kubota, Byoung Chul Cho, Vichien Srimuninnimit, Yu Fan, Jianying Zhou, Li Zhang, Qing Zhou, Yukio Hosomi, Hiroaki Takeoka, Rinee Mukherjee, Wei Fu, Fabricio Souza, Tony S.K. Mok, Li Zhang
Journal: Annals of Oncology (2022)
MO18-2 A phase II trial of neoadjuvant apatinib combined with nab-paclitaxel and carboplatin in triple-negative breast cancer
Authors: Tianyu Zeng, Jue Wang, Wei Li, Chunxiao Sun, Fan Yang, Yan Liang, Ziyi Fu, Xiaoming Zha, Yongmei Yin
Journal: Annals of Oncology (2022)
MO38-1 Phase I study of BI 836880 alone or combined with ezabenlimab in Japanese patients (pts) with advanced solid tumors
Authors: Kentaro Yamazaki, Takafumi Koyama, Toshio Shimizu, Akiko Todaka, Takeshi Kawakami, Jangsoo Yoon, Damijan Erzen, Jianrui Hou, Noboru Yamamoto
Journal: Annals of Oncology (2022)
MO31-2 Telisotuzumab vedotin monotherapy in patients with previously treated c-Met+ advanced non-small cell lung cancer
Authors: Hidehito Horinouchi, J.W. Goldman, F. Moiseenko, I. Cicin, E. Filippova, J. Bar, P. Tomasini, C. Ocampo, D. Sullivan, D. Maag, M. Motwani, J. Jin, D.R. Camidge
Journal: Annals of Oncology (2022)
P74-1 Encorafenib, binimetinib, and cetuximab combination therapy for patients with BRAF V600E mutant colorectal cancer
Authors: Kazuki Moro, Takuro Saiki, Kenta Sasaki, Akio Matsumoto, Qiliang Zhou, Mae Nakano, Masato Nakano, Yoshifumi Matsumoto, Yoshifumi Shimada, Masato Moriyama, Toshifumi Wakai, Yasuo Saijo
Journal: Annals of Oncology (2022)
MO10-4 Novel non-invasive biomarkers for the detection of myelofibrosis in patients with myeloproliferative neoplasms
Authors: Takaaki Maekawa, Tomoyuki Yoshikawa, Miki Moriiwa, Aoi Hirata, Yukihiro Shimizu, Hiraku Ogata, Keita Saito, Takuya Izumi, Shigeki Nagao, Kosuke Takano, Yosuke Okada, Noriaki Tachi, Masahiro Teramoto, Toshikuni Kawamura, Toshikatsu Horiuchi, Shoichiro Kato, Ayako Kobayashi, Shinichi Kobayashi, Hiroyuki Kawaguchi, Fumihiko Kimura
Journal: Annals of Oncology (2022)
MO5-2 Cabozantinib may enhance efficacy of anti-PD-1 therapy in hepatocellular carcinoma through suppression of MDSCs
Authors: Da-Liang Ou, Li Lin, Chia-Lang Hsu, Cheng-Zhe Jian, Bin-Shyun Lee, Ann-Lii Cheng, Chiun Hsu
Journal: Annals of Oncology (2022)
P28-14 Long-term response to alectinib in a patient with ALK-fusion gene emerged in afatinib-resistant EGFR-mutated lung cancer
Authors: Emiko Uji, Nobuaki Ochi, Hiromichi Yamane, Yasunari Nagasaki, Tatsuyuki Kawahara, Masataka Taoka, Youko Kosaka, Kouhei Takeda, Hidekazu Nakanishi, Takigawa Nagio
Journal: Annals of Oncology (2022)
MO30-1 Factors critical for the acquisition of antibody after SARS-CoV-2 vaccination in malignant lymphoma patients
Authors: Akinao Okamoto, Fujigaki Hidetsugu, Iriyama Chisako, Goto Naoe, Yamamoto Hideyuki, Mihara Keichiro, Inaguma Yoko, Miura Yasuo, Furukawa Katsuya, Yamamoto Yukiya, Akatsuka Yoshiki, Kasahara Senji, Miyao Kotaro, Masataka Okamoto, Kuniaki Saito, Akihiho Tomita
Journal: Annals of Oncology (2022)
P9-7 Treatment outcome following nivolumab therapy administered after radiation therapy for esophageal cancer
Authors: Fumitaka Endo, Yuji Akiyama, Shigeaki Baba, Haruka Nikai, Akira Umemura, Hirokatsu Katagiri, Takeshi Iwaya, Koki Otsuka, Hiroyuki Nitta, Keisuke Koeda, Akira Sasaki
Journal: Annals of Oncology (2022)
MO35-2 Symptom monitoring and its digitalization at daily cancer chemotherapy in Japan: a nation-wide multi-stakeholder survey
Authors: Yoshiki Horie, Tempei Miyaji, Takashi Kawaguchi, Takako Kaneyasu, Fumio Nagashima, Ayako Doi, Yu Uneno, Takashi Ogura, Takuhiro Yamaguchi, Takako Nakajima
Journal: Annals of Oncology (2022)
MO8-3 Real-world outcomes of systemic therapy in Japanese cancer patients: Tokushukai REAl-world Data project (TREAD)
Authors: Rai Shimoyama, Yoshinori Imamura, Kiyoaki Uryu, Takahiro Mase, Yoshiaki Fujimura, Maki Hayashi, Megu Ohtaki, Keiko Otani, Hironobu Minami, Nobuaki Shinozaki
Journal: Annals of Oncology (2022)
MO13-1 Geriatric-8 scores of elderly Japanese patients with cancer at the introduction of chemotherapy; A retrospective study
Authors: Kohji Takemura, Annop Kittiwarawut, Taro Yamanaka, Kazumasa Yamamoto, Shogo Watanabe, Toshiaki Takahashi, Yosuke Aoyama, Koichiro Yoshino, Rika Kizawa, Takeshi Yamaguchi, Yuko Tanabe, Koichi Suyama, Yuji Miura
Journal: Annals of Oncology (2022)
P28-11 The therapeutic efficacy of osimertinib in non-small cell lung cancer with malignant pleural effusion
Authors: Hiroaki Nagamine, Kenji Sawa, Hiroyasu Kaneda, Koichi Ogawa, Kenji Nakahama, Yoshiya Matsumoto, Yoko Tani, Shigeki Mitsuoka, Tatsuo Kimura, Tomoya Kawaguchi
Journal: Annals of Oncology (2022)
P25-5 Effective treatment of chemotherapy with EGFR Ab for an unresectable Lynch syndrome-associated small intestinal cancer
Authors: Atsushi Toyofuku, Koki Oyama, Akihiro Kubo, Yuki Koreeda, Kohei Yoshida, Takefumi Katsuki, Aiichiro Higure, Shinji Yotsumoto, Naoki Nagata
Journal: Annals of Oncology (2022)
PS3-4 Oxaliplatin with FU plus BEV in elderly pts with metastatic colorectal cancer: a phase III trial of JCOG1018 (RESPECT)
Authors: Atsuo Takashima, Tetsuya Hamaguchi, Junki Mizusawa, Shimada Yasuhiro, Fumio Nagashima, Masahiko Ando, Shu Okamura, Manabu Shimomura, Kenji Katsumata, Manabu Shiozawa, Yasumasa Takii, Akio Shiomi, Satoshi Ootsu, Tohru Funakoshi, Rei Hirata, Tetsu Yamamoto, Masahito Kotaka, Hiroshi Katayama, Kenichi Nakamura, Yukihide Kanemitsu
Journal: Annals of Oncology (2022)
Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial
Authors: Doortje I Krijbolder, Marloes Verstappen, Bastiaan T van Dijk, Yousra J Dakkak, Leonie E Burgers, Aleid C Boer, Yune Jung Park, Marianne E de Witt-Luth, Karen Visser, Marc R Kok, Esmeralda T H Molenaar, Pascal H P de Jong, Stefan Böhringer, Tom W J Huizinga, Cornelia F Allaart, Ellis Niemantsverdriet, Annette H M van der Helm-van Mil
Journal: The Lancet (2022)
O17-1 A phase II trial of nivolumab, gemcitabine and S-1 as the frst-line treatment in patients with biliary tract cancer
Authors: Ming-Huang Chen, Nai-Jung Chiang, Li-Yuan Bai, Chien-Jui Huang, San-Chi Chen, Chin-Fu Hsiao, Yan-Shen Shan, Yung-Yeh Su, Li-Tzong Chen
Journal: Annals of Oncology (2022)
P21-17 Safety and effectiveness of mirogabalin for CIPN induced by nab-paclitaxel in patients with pancreatic cancer
Authors: Kei Saito, Yousuke Nakai, Kazunaga Ishigaki, Naminatsu Takahara, Tatsunori Suzuki, Ryunosuke Hakuta, Tomotaka Saito, Tsuyoshi Hamada, Suguru Mizuno, Hirofumi Kogure, Mitsuhiro Fujishiro
Journal: Annals of Oncology (2022)
O1-6 REVIVE study: An observational study in chemotherapy (CTx) after nivolumab (NIVO) for advanced gastric cancer (AGC)
Authors: Yasuhiro Sakamoto, Yukiya Narita, Toshihiro Misumi, Hiroshi Matsuoka, Hiroaki Tanioka, Takeshi Kawakami, Tomohiro Matsushima, Hiroto Miwa, Hirokazu Shoji, Atsushi Ishiguro, Sachio Fushida, Kou Miura, Takanobu Yamada, Katsunori Shinozaki, Takuro Mizukami, Tomohiro Nishina, Toshikazu Moriwaki, Seiichiro Mitani, Michio Nakamura, Kei Muro
Journal: Annals of Oncology (2022)
O13-1 Phase II study of brigatinib in ROS1-positive non-small cell lung cancer patients previously treated with crizotinib
Authors: Yasushi Goto, Seiji Niho, Haruko Daga, Sakakibara-Konishi Sakakibara-Konishi, Hiroshi Tanaka, Kadoaki Ohashi, Ryo Toyozawa, Masahiro Kotani, Toshiaki Takahashi, Yoshihiro Hattori, Masahiro Morise, Takaya Ikeda, Shingo Matsumoto, Kiyotaka Yoh, Shogo Nomura, Koichi Goto
Journal: Annals of Oncology (2022)
O18-6 Safety of encorafenib, binimetinib, plus cetuximab for Japanese patients with BRAF V600E metastatic colorectal cancer
Authors: Toshifumi Yamaguchi, Kotani Daisuke, Takashima Atsuo, Kato Takeshi, Masuishi Toshiki, Komatsu Yoshito, Shiozawa Manabu, Esaki Taito, Izawa Naoki, Takeuchi Shinji, Bando Hideaki, Iwasa Satoru, Hasegawa Hiroko, Satoh Taroh, Taniguchi Hiroya, Yoshino Takayuki
Journal: Annals of Oncology (2022)
MO37-3 Clinical characteristics of 145 patients with adrenal insufficiency related to immune checkpoint inhibitor
Authors: Miyuki Uoi, Junko Tauchi, Kaoru Koshiba, Daisuke Hisamatsu, Atsushi Miyada, Haruna Kameoka, Shinya Takada, Takuya Hiromasa, Reiko Matsui, Ken Ohashi, Toshikatsu Kawasaki
Journal: Annals of Oncology (2022)
P69-8 Effectiveness of the Early Palliative Care Intervention Program on depression and anxiety: A randomized controlled trial
Authors: Ayumi Okizaki, Matsumoto Yoshihisa, Fujisawa Daisuke, Kiuchi Daisuke, Shigeki Umemura, Takuhiro Yamaguchi, Syunsuke Oyamada, Naoko Kobayashi, Tempei Miyaji, Tomoe Mashiko, Eriko Satomi, Masanori Mori, Koichi Goto, Yuichiro Ohe, Yosuke Uchitomi, Tatsuya Morita
Journal: Annals of Oncology (2022)
Adults with symptoms of pneumonia: a prospective comparison of patients with and without infiltrates on chest radiography
Authors: Kristján Godsk Rögnvaldsson, Agnar Bjarnason, Inga Sif Ólafsdóttir, Kristján Orri Helgason, Aðalsteinn Guðmundsson, Magnús Gottfreðsson
Journal: Clinical Microbiology and Infection (2022)

Most studies on patients hospitalized with community-acquired pneumonia (CAP) require confirmation of an infiltrate by chest radiography, but in practice admissions are common among patients with symptoms of pneumonia without an infiltrate (SPWI). The aim of this research was to compare clinical characteristics, microbial etiology, and outcomes among patients with CAP and SPWI.Adults suspected of CAP were prospectively recruited at Landspitali University Hospital over a 1-year period, 2018 to 2019. The study was population based. Those admitted with two or more of the following symptoms were invited to participate: temperature ≥38°C or ≤36°C, sweating, shaking/chills, chest pain, a new cough, or new onset of dyspnea. Primary outcome was mortality at 30 days and one year.Six hundred twenty-five cases were included, 409 with CAP and 216 with SPWI; median age was 75 (interquartile range [IQR] 64-84) and 315 (50.4%) were females. Patients with CAP were more likely to have fever (≥38.0°C) (66.9% [273/408]) vs. 49.3% (106/215), p < 0.001), a higher CRP (median 103 [IQR 34-205] vs. 55 (IQR 17-103), p < 0.001), identification of Streptococcus pneumoniae (18.0% [64/355]) vs. 6.3% (10/159) of tested, p = 0.002) and to receive antibacterial treatment (99.5% [407/409]) vs. 87.5% (189/216), p < 0.001) but less likely to have a respiratory virus detected (25.4% [33/130]) vs. 51.2% (43/84) of tested, p < 0.001). The adjusted odds ratios for 30-day and 1 year mortality of SPWI compared to CAP were 0.86 (95% CI 0.40-1.86) and 1.46 (95% CI 0.92-2.32), respectively.SPWI is a common cause of hospitalization and despite having fever less frequently, lower inflammatory markers, and lower detection rate of pneumococci than patients with CAP, mortality is not significantly different.
P51-8 Biweekly administration of cetuximab in Japanese patients with recurrent or metastatic head and neck cancer
Authors: Nobukazu Tanaka, Tomohiro Enokida, Takao Fujisawa, Masanobu Satou, Akihisa Wada, Hideki Tanaka, Naohiro Takeshita, Susumu Okano, Makoto Tahara
Journal: Annals of Oncology (2022)
PS2-2 KEYNOTE-355 Asian subset: Pembrolizumab + chemotherapy vs placebo + chemotherapy for triple-negative breast cancer
Authors: Toshimi Takano, Javier Cortes, David W. Cescon, Seock-Ah Im, Mastura Md Yusof, Hiroji Iwata, Norikazu Masuda, Chiun-Sheng Huang, Chi-Feng Chung, Koichiro Tsugawa, Yeon Hee Park, Koji Matsumoto, Kenichi Inoue, Ava Kwong, Sherene Loi, Wei Fu, Wilbur Pan, Valia Karantza, Hope S. Rugo, Peter Schmid
Journal: Annals of Oncology (2022)
PS4-2 Analysis of the COLLECT Study - Efficacy and safety of lenvatinib in differentiated thyroid cancer
Authors: Hiroyuki Iwasaki, Hiroshi Takami, Ito Yasuhiro, Okamoto Takahiro, Sugitani Iwao, Sugino Kiminori, Takahashi Shunji, Takeyama Hiroshi, Tutui Hidemitsu, Hara Hisato, Mitsuma Ayako, Yamashita Hiroyuki, Ohashi Yasuo, Shiroiwa Takeru, Imai Tuneo, Tahara Makoto
Journal: Annals of Oncology (2022)
MO23-6 A single-center experience of comprehensive genomic profiling of hepatobiliary and pancreatic cancers
Authors: Hiroki Eguchi, Hiroshi Imaoka, Kanae Inoue, Tomonao Taira, Kei Okumura, Taro Shibuki, Kazuo Watanabe, Mitsuhito Sasaki, Shuichi Mitsunaga, Masafumi Ikeda
Journal: Annals of Oncology (2022)
MO20-2 Efficacy of immune checkpoint inhibitors for gastrointestinal cancers with SWI/SNF complex genetic alterations
Authors: Akinobu Nakata, Yukiya Narita, Ryosuke Kumanishi, Taiko Nakazawa, Takatsugu Ogata, Yuki Matsubara, Hiroyuki Kodama, Kazunori Honda, Toshiki Masuishi, Hiroya Taniguchi, Shigenori Kadowaki, Masashi Ando, Rui Yamaguchi, Masahiro Tajika, Kei Muro
Journal: Annals of Oncology (2022)
P5-6 Clinical feasibility and current trends of approved multigene panels in a genomic medicine cooperative hospital
Authors: Nahomi Tokudome, Hiroki Ueda, Yuta Hamano, Ashida Reiko, Yasuhiro Koh, Yuichi Ozawa, Kenji Matsuda, Seiji Kanno, Kazuroh Yoshikawa, Miwako Miyasaka, Yuki Yamamoto, Sawako Minami, Shinichi Murata, Nobuyuki Yamamoto
Journal: Annals of Oncology (2022)
MO8-5 Evaluation of geriatric assessment for chemotherapy in older patients with gastrointestinal or biliary pancreatic cancer
Authors: Shoko Inoo, Yoshiyasu Kono, Hiromitsu Kanzaki, Shigeru Horiguchi, Hironari Kato, Yasushi Yamasaki, Tatsuya Kikuchi, Sakiko Kuraoka, Shotaro Okanoue, Takuya Satomi, Kenta Hamada, Masaya Iwamuro, Seiji Kawano, Hiroyuki Okada
Journal: Annals of Oncology (2022)